Jun 2005
Report Five: Grid Computing – Adoption in the Pharmaceutical Sector

Pharmaceutical firms have a clear need for greater computing power. The major companies are investigating up to 10,000 diseases and are searching through databases containing millions of compounds and proteins. Research teams are often scattered across various countries, especially since many pharmaceutical firms have grown through acquisition, and improving communication and interaction among these groups is a major challenge. The pharmaceutical sector has been viewed as a natural adopter of grid computing, given its need for high computing power and its link with grids in the academic sector. Yet The 451 Group has found a wide range of adoption strategies in this sector, and there are some firms that see no real need for grid computing.

This report analyzes the adoption of grid technology in the pharmaceutical sector. It examines the current and future strategies of 11 pharmaceutical and biotech firms, including four of the global top 10. The report also analyzes the approach and strategies of 10 vendors, from the industry giants to the drug discovery software firms.

> Early-adopter case studies: Cognigen, De Novo Pharmaceuticals, DiaDexus, Entelos, GlaxoSmithKline, Incyte, Inpharmatica, Johnson & Johnson, Novartis, Protana and Sanofi-Aventis.

> Vendor assessments: Accelrys, Data-Grid, Hewlett-Packard, IBM, Platform Computing, Schrodinger, Sun Microsystems, Tripos, TurboWorx and United Devices.

For more details about this report or about the 451 Grid Adoption Research Service in general, please fill out the form above, or contact our sales staff:

By email at , or by phone at 212 505 3030 in the US.

Note to Clients: If you have purchased access to this service, you may access it by going to Grid Adoption Research Service on the Client Access menu at left and logging in. If the reports do not appear for download after logging in, please contact your Client Account Manager, who can enable access.

About The 451 Group

The 451 Group is an independent technology industry analyst company focused on the business of enterprise IT innovation. The company’s analysts provide critical and timely insight into the market and competitive dynamics of innovation in emerging technology segments. Clients of the company – at vendor, investor, service- provider and end-user organizations – rely on 451 insight to support both strategic and tactical decision-making for competitive advantage.

The 451 Group is headquartered in New York, with offices in key locations, including San Francisco, London and Boston. For additional information on the company or to apply for trial access to its services, go to: www.the451group.com